February 18, 2007 – Last week, the Centient Biotech 200™ rose just 4 points, which equates to a small one-tenth of one percentage point, ending at 4054. Breadth was slightly negative, though not so much that it could be called a divergence. The IPO market took a week off, and it will do the same in the upcoming week. SGX Pharma was the best performer in the hot recent-IPO group. Onyx led all biotech with a 126% gain on the strength of a strong showing for Nexavar; Dyax enjoyed a 34% run-up after a Motley Fool profile; CytRx was 26% higher on a BusinessWeek write-up; and GPC rose after completing its satraplatin application. More details...
